ADMA Biologics-Adma Biologics (ADMA) Increases Yet Falls Behind Market: What Investors Need to Know

Group 1 - Adma Biologics closed at $23.52, with a +1.07% change, underperforming the S&P 500's daily gain of 1.47% [1] - Over the past month, shares of Adma Biologics gained 19.64%, outperforming the Medical sector's loss of 2.95% and the S&P 500's loss of 0.47% [1] Group 2 - The upcoming earnings release on May 7, 2025, is expected to show an EPS of$ 0.16, a 100% increase from the same quarter last year, with projected net sales of $119.1 million, up 45.46% year-over-year [2] - For the full year, analysts expect earnings of$ 0.71 per share and revenue of $495.8 million, reflecting changes of +44.9% and +16.26% respectively from the previous year [3] Group 3 - Changes in analyst estimates for Adma Biologics are important as they reflect short-term business trends and analysts' confidence in the company's performance [4] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), indicates that Adma Biologics currently holds a Zacks Rank of 2 (Buy) [6] Group 4 - Adma Biologics has a Forward P/E ratio of 32.78, which is a premium compared to the industry average Forward P/E of 17.32 [7] - The Medical - Biomedical and Genetics industry, which includes Adma Biologics, holds a Zacks Industry Rank of 84, placing it in the top 35% of over 250 industries [7]